New MRI Finds Hidden Spinal Cord Damage in MS

Credibility

Interest

Key Takeaway

A very detailed MRI method at 7 Tesla can pick up both visible and hidden spinal cord damage in MS and show individual patients how much tissue is affected.

What They Found

Using a high-resolution 7 T MRI scan, researchers measured a property called T1 that changes when spinal cord tissue is damaged; higher T1 means more abnormal tissue.Lesions were most often in the back (posterior) part of the spinal cord, and gray matter (the part with nerve cell bodies) had the highest share of lesion tissue, though no lesion was found only in gray matter.Areas that looked normal on regular images still showed higher T1 in MS patients than in healthy people, suggesting there is hidden or diffuse damage beyond the spots you can see.Lesions that involved both gray and white matter were larger and had higher T1 than lesions only in white matter, meaning mixed lesions may be worse for tissue health.The team made individual Z-score charts for each patient so you can see, at a glance, how many spinal cord brain-image spots (voxels) are abnormal for that person — over 10% abnormal was seen in more than half of the patients.

Who Should Care and Why

MS patients and caregivers should care because this method can show not just obvious lesions but also subtle damage that might explain symptoms like weakness, numbness, or balance trouble even when regular scans look mild.Clinicians and therapists can use this kind of detailed information to better match treatments and rehabilitation to the specific areas of the spinal cord that are affected — like tailoring physical therapy to motor-tract damage.Patients considering new or neuroprotective treatments may benefit because this scan and the Z-score charts could help track small changes over time, like checking whether a therapy is protecting the spinal cord.Caregivers can use the idea of an individualized bar chart (Z-score) like a progress report: it makes it easier to see if damage is stable, getting worse, or improving, which helps plan care and daily activities.People with MS who have symptoms but normal standard scans might be reassured that there are ways to detect hidden injury; this could lead to earlier adjustments in medication or lifestyle to protect function.

Important Considerations

This was a small, exploratory study (15 MS patients), so the findings need confirmation in larger groups before being used widely in clinical care.7 Tesla MRI machines are not common in routine hospitals, so this specific scan might not be easy to get for many patients right now.Higher T1 values suggest tissue changes but do not directly tell us the exact cause (for example inflammation vs long-term scarring), so results should be combined with clinical exams and other tests.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Early Research MS Progression

Article Topics:

7 TeslaMP2RAGEMS lesionT1 mappingZ-scorecross-sectional areagray matter MSmultiple sclerosis (MS)normal-appearing tissuespinal cord

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Investigative radiology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News